Lexeo Therapeutics (LXEO) Competitors $4.12 -0.32 (-7.21%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$4.16 +0.04 (+1.09%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO vs. IOVA, ARVN, SAGE, AMLX, TBPH, ATAI, KROS, TLRY, MNMD, and ORGOShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Iovance Biotherapeutics (IOVA), Arvinas (ARVN), Sage Therapeutics (SAGE), Amylyx Pharmaceuticals (AMLX), Theravance Biopharma (TBPH), atai Life Sciences (ATAI), Keros Therapeutics (KROS), Tilray Brands (TLRY), Mind Medicine (MindMed) (MNMD), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. Its Competitors Iovance Biotherapeutics Arvinas Sage Therapeutics Amylyx Pharmaceuticals Theravance Biopharma atai Life Sciences Keros Therapeutics Tilray Brands Mind Medicine (MindMed) Organogenesis Lexeo Therapeutics (NASDAQ:LXEO) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations. Which has better earnings and valuation, LXEO or IOVA? Lexeo Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo TherapeuticsN/AN/A-$98.33M-$3.30-1.25Iovance Biotherapeutics$212.68M3.05-$372.18M-$1.24-1.56 Is LXEO or IOVA more profitable? Lexeo Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -176.49%. Iovance Biotherapeutics' return on equity of -49.71% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -85.86% -68.48% Iovance Biotherapeutics -176.49%-49.71%-39.18% Do institutionals & insiders have more ownership in LXEO or IOVA? 60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 5.3% of Lexeo Therapeutics shares are held by insiders. Comparatively, 10.3% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, LXEO or IOVA? Lexeo Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Do analysts rate LXEO or IOVA? Lexeo Therapeutics currently has a consensus price target of $16.60, suggesting a potential upside of 302.91%. Iovance Biotherapeutics has a consensus price target of $12.22, suggesting a potential upside of 530.01%. Given Iovance Biotherapeutics' higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Lexeo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Iovance Biotherapeutics 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media favor LXEO or IOVA? In the previous week, Iovance Biotherapeutics had 41 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 43 mentions for Iovance Biotherapeutics and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.45 beat Iovance Biotherapeutics' score of 0.19 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iovance Biotherapeutics 4 Very Positive mention(s) 3 Positive mention(s) 32 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryIovance Biotherapeutics beats Lexeo Therapeutics on 8 of the 14 factors compared between the two stocks. Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$136.77M$2.44B$5.61B$9.29BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-1.259.1428.5419.58Price / SalesN/A683.96430.1194.56Price / CashN/A164.3436.0257.93Price / Book1.174.608.145.54Net Income-$98.33M$30.99M$3.24B$257.73M7 Day Performance-10.43%-1.81%0.17%-0.08%1 Month Performance5.10%5.73%5.95%8.09%1 Year Performance-67.41%-7.03%26.22%13.02% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics2.0204 of 5 stars$4.12-7.2%$16.60+302.9%-68.3%$136.77MN/A-1.2558IOVAIovance Biotherapeutics4.6895 of 5 stars$1.70-2.9%$12.22+619.0%-77.6%$584.39M$164.07M-1.37500Trending NewsAnalyst DowngradeGap DownARVNArvinas3.9779 of 5 stars$7.79-2.0%$20.29+160.5%-75.3%$580.28M$263.40M-11.80420News CoverageSAGESage Therapeutics3.4125 of 5 stars$9.17-0.3%$8.93-2.6%-22.3%$576.11M$41.24M-1.58690AMLXAmylyx Pharmaceuticals3.3772 of 5 stars$6.76+7.3%$11.00+62.7%+275.9%$561.59M-$1.27M-2.17200TBPHTheravance Biopharma1.7662 of 5 stars$11.31+1.4%$16.60+46.8%+16.8%$557.52M$64.38M-9.58110ATAIatai Life Sciences3.1684 of 5 stars$2.75-0.7%$9.00+227.3%+64.6%$554.93M$310K-3.0280Gap UpHigh Trading VolumeKROSKeros Therapeutics2.0753 of 5 stars$13.40-0.4%$30.56+128.0%-72.1%$546.28M$3.55M-74.44100TLRYTilray Brands1.8698 of 5 stars$0.50-6.6%$1.92+280.7%-68.9%$542.20M$788.94M-0.482,650MNMDMind Medicine (MindMed)2.1969 of 5 stars$7.20+0.4%$25.50+254.2%+3.2%$541.72MN/A-5.5840Positive NewsORGOOrganogenesis4.4748 of 5 stars$4.25flat$6.00+41.2%+39.4%$539.13M$482.04M-25.00950News CoverageAnalyst ForecastGap Down Related Companies and Tools Related Companies Iovance Biotherapeutics Competitors Arvinas Competitors Sage Therapeutics Competitors Amylyx Pharmaceuticals Competitors Theravance Biopharma Competitors atai Life Sciences Competitors Keros Therapeutics Competitors Tilray Brands Competitors Mind Medicine (MindMed) Competitors Organogenesis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXEO) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
